Funding Opportunity RFA-CA-19-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches. The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the United States (U.S.) population. The UG3/UH3 projects in response to this FOA must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development of one-year, milestone-driven planning phase (UG3), with possible rapid transition to the second phase (UH3) for clinical trials. UH3s will be awarded after administrative review of eligible UG3s that have met the scientific milestones and feasibility requirements necessary for the UH3 phase, depending on availability of funds.

Negotiable: Paramount Recruitment: Software Developer Cancer Diagnostics, Bioinformatics, Permanent A fantastic new opportunity has become available for an experienced Software Developer to join a Biotechnology company in the Hamburg region. Hamburg, Germany

Funding Opportunity PA-19-050 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care. The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Funding Opportunity PA-19-042 from the NIH Guide for Grants and Contracts. Standard AIDS dates apply , by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. The first application due date for this FOA is January 7, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Interaction across company, in particular with bioinformatics team members who use R&D genomics tools for application to diagnostic system....
From Indeed - Wed, 31 Oct 2018 18:11:38 GMT - View all Redmond, WA jobs

Interaction across company, in particular with bioinformatics team members who use R&D genomics tools for application to diagnostic system....
From Indeed - Wed, 31 Oct 2018 18:07:54 GMT - View all Kirkland, WA jobs

Funding Opportunity PA-19-043 from the NIH Guide for Grants and Contracts. Genome-wide association studies and other disease studies have identified many variants that are statistically associated with disease risk, disease protection, or other traits. However, such studies do not generally show which specific variants in genomic elements cause these effects, or how they result in differences in function. Similarly, genomic sequencing studies in clinical settings have identified many variants in healthy and diseased individuals. However, the pathogenicity of such variants is often unknown, leading to their classification as variants of uncertain significance (VUS), which makes clinical implementation difficult. This Program Announcement which has companion R21 and R01 Program Announcements aims to support the development of novel and generalizable commercialized approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically.

Funding Opportunity PA-19-046 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks Exploratory/Developmental Research Grants (R21) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments, (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. Augmentative and alternative communication (AAC) helps millions worldwide who cannot rely on their natural speech to communicate. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.

Funding Opportunity PA-19-047 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments, (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. Augmentative and alternative communication (AAC) helps millions worldwide who cannot rely on their natural speech to communicate. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational.

Negotiable: Paramount Recruitment: Senior Cancer Bioinformatician 100,000 Genomes Project - Bioinformatics - Central London! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Funding Opportunity PAR-19-045 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.

Funding Opportunity PAR-19-044 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.

Competitive Salary: EMBL: Bioinformatics Software Engineer and Data Manager Lo Germany (DE)

Funding Opportunity RFA-DK-18-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).

Funding Opportunity RFA-CA-19-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The purpose of this FOA is to expand organ site-specific Cancer Immunotherapy Research Projects as components of the Immuno-Oncology Translation Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.

Funding Opportunity RFA-CA-19-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this specific FOA is to establish Cancer Immunoprevention Research Projects that will function as components of a Cancer Immunotherapy Consortium (CIC), which will also include Cancer Immunotherapy Research Projects. The CIC will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression, and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications.

Funding Opportunity RFA-CA-19-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The purpose of this FOA is to employ immuno-engineering principles to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies. The Immuno-engineering to Improve Immunotherapy (i3) Centers will be comprised of multi-disciplinary teams focused on designing and evaluating innovative engineered immunotherapy approaches and collaborating with the Immuno-Oncology Translational Network (IOTN) investigators to improve existing immunotherapeutic modalities.

Funding Opportunity RFA-CA-19-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Exploratory studies aimed at immune target identification and validation will be supported under UG3. Achievement of the UH2 milestones will be necessary for transition to the UH3 Implementation Phase. UH3 phase may be awarded after administrative review of the UH2 milestones. Provided these milestones are achieved, UH3 phase may continue with development and preclinical testing of specific interventions.

Notice NOT-HL-18-661 from the NIH Guide for Grants and Contracts

Notice NOT-AA-18-012 from the NIH Guide for Grants and Contracts